Altimmune

Q2 FY2026 EarningsQ2 FY2026 results were generally in line with or slightly better than consensus: GAAP EPS loss of $0.12 beat the $0.1385 expected loss. Revenue was $0 as anticipated for this clinical-stage firm. Net loss of $22.8M was narrower than the $25.1M consensus loss, primarily due to higher interest income of $4.5M. Clinical momentum remains strong with the initiation of the Phase 3 PERFORMA MASH trial and positive Phase 2 RECLAIM data in AUD, while a cash position of $519M provides substantial runway for upcoming trials.